Ajanta Pharma Reappoints Internal, Cost, and Tax Auditors for FY27
Ajanta Pharma's Board, in a meeting on May 5, 2026, re-appointed M/s. Aneja Assurance Pvt. Ltd. as Internal Auditors, M/s. RA & Co. as Cost Auditors, and M/s. R S Sanghai & Associates as Tax Auditors for FY 2026-27.
The re-appointment of auditors is a routine administrative task for the company and is unlikely to have a significant impact on its financial performance or stock price.
The announcement pertains to the routine re-appointment of auditors, which is a standard corporate procedure and does not inherently carry a positive or negative financial implication.
Ajanta Pharma Limited announced that its Board of Directors, in a meeting held on Tuesday, 5th May 2026, approved the re-appointment of key audit firms for the financial year 2026-27.
M/s. Aneja Assurance Pvt. Ltd. has been re-appointed as the Internal Auditors of the Company for FY 2026-27. Aneja Assurance Pvt. Ltd. is a Mumbai-based firm with over 40 years of experience in internal audit and risk advisory, specializing in pharmaceuticals, BFSI, and manufacturing sectors.
M/s. RA & Co., Cost Accountants, has been re-appointed as the Cost Auditors for FY 2026-27, in accordance with Section 148 of the Companies Act, 2013. RA & Co. is a Cost & Management Consultancy firm with decades of professional experience across India.
M/s. R S Sanghai & Associates, Chartered Accountants, has been re-appointed as the Tax Auditors for FY 2026-27. The firm is known for its expertise in direct and indirect tax laws and timely delivery of quality solutions.
All re-appointments were effective from 5th May 2026. There are no disclosed relationships between the company's directors and these audit firms.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under auditor changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.